WeChat Mini Program
Old Version Features

Cost-effectiveness and Return on Investment of Hepatitis C Virus Elimination in China: A Modelling Study

Clinical and molecular hepatology(2024)SCI 2区SCI 3区

Cited 0|Views10
Abstract
BACKGROUND/AIMS:The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination. METHODS:Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022-2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths. RESULTS:The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022-2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868). CONCLUSION:Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
More
Translated text
Key words
hepatitis c,disease eradication,cost-effectiveness analysis,outcome assessment, health care,china
求助PDF
上传PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:本研究评估了中国实现丙型肝炎病毒(HCV)根除的健康效益、成本效益及投资回报,提出了一种具有成本效益的根除策略。

方法】:利用HCV传播分舱模型评估了结合筛查和治疗的不同策略对中国人群的效益和成本,计算了2022-2030年避免残疾调整生命年(DALY)的增量成本效益比(ICER),并估算到2050年的投资回报率。

实验】:研究通过模型得出,在2022-2030年间实施每年14%的初筛、每年对注射毒品者(PWID)进行重筛、每五年对一般人群进行一次重筛,并对95%的诊断患者进行治疗(P14-R4-T95)的策略,可预防约575,000例HCV感染和440,000例死亡。该策略在愿意支付阈值$12,615时最具成本效益,其ICER为$5,449/DALY。到2050年,此策略将有1,209,970万美元的净收益(ROI=0.868)。